- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803151
A Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy
A Prospective Phase II Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy
Lymph node metastasis is one of the most common sites to develop disease recurrence or progression after initial local treatment for primary solid malignancies or systemic treatment for advanced metastases. No specific treatment modality has been established as the standard therapy. Systemic therapy is usually considered since lymphadenopathy is considered as a sign of disease dissemination though aggressive local treatment, including surgical lymphoadenectomy or radical radiotherapy might result in long-term survival in selected patients. The concept of stereotactic ablative radiotherapy (SABR), a high dose of radiation targeted to a pathological entity and delivered in a few fractions, has proven so successful at treating both benign and malignant lesions that it changed the paradigm for radiation therapy. The radiobiology of SABR has been shown to be very favorable for tumor control. Clinical experiences suggested that SABR might offer excellent in-field tumor control with low toxicity profile in selected patients, although the majority of reports are retrospective and include small patients series with heterogeneous tumor sites and dose-fractionation schedules.
At present, there is lack of validated prognostic factors to identify the patients who might benefit most from ablative local therapy for metastatic lymph node(s). The mechanism of effect of SABR on the cancer lesions is not yet clear. Apart from its direct effect on clonogenic cancer cells, an immune-mediated process was also hypothesized. Therefore, the present study is aimed to provide a better understanding about utilization of SABR for metastatic lymph node(s). The associated translational researches will also advance our knowledge in the immune system reactions to SABR.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single institutional, single-arm, phase II trial to assess the local control rate of oligo-metastatic or oligo-progressive lymph node treated by stereotactic ablative radiotherapy at 1 year.
Patients with pathologically proven non-hematopoietic malignancy patients with radiographic evidence of evaluable regional recurrent, oligo-metastatic or oligo-progressive lymph nodes are eligible for enrolment.
Stereotactic Ablative Radiotherapy:
The lymph node planning target volume (PTV) will receive the prescribed dose according to the assigned treatment group. The dose is prescribed such as 90-95% of PTV is covered by the prescription dose. If the critical structures exceed the defined dose limitation, a dose reduction method is applied as protocol defined. Dose inhomogeneity can exist within the clinical target volume (CTV).
Treatment will be delivered in six fractions to the target volume and given once per day, 2-3 fractions per week with no more than 2 daily consecutive fractions, over 2 to 2.5 weeks.
Target Radiation Dose: SABR with 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Radiation Dose Reduction:
Reduced Dose 10%: SABR with 40.05 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria
Reduced Dose 20%: SABR with 36 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chiao-Ling Tsai, MD
- Phone Number: 62643 +886-2-23123456
- Email: chiaoling@ntuh.gov.tw
Study Contact Backup
- Name: Feng-Ming Hsu, MD
- Phone Number: 67061 +886-2-23123456
Study Locations
-
-
-
Tapei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Feng-Ming Hsu, MD
- Phone Number: 67061 886-2-23123456
- Email: hsufengming@ntuh.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Patients with a histologic diagnosis of non-hematopoietic malignancy
- Radiographic evidence of measurable enlarged metastatic lymph node(s) with short-axis ≥ 1 cm
- Patients do not have prior radiotherapy to the index node(s)
- Age ≥ 20 years
- Karnofsky performance status (KPS) ≥ 60%.
- Life expectancy of ≥ 4 month
- Patients must have adequate renal function with serum creatinine ≤ 2.0 mg/dL measured within 90 days prior to registration
- Women of childbearing potential and male participants must practice adequate contraception
- Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent
Exclusion criteria
- Prior radiotherapy to the index metastatic lymph node(s)
- Sum of the greatest dimensions of index lymph note(s) exceed 6 cm
- Inability to achieve the minimal required radiation dose (36Gy)
Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:
- Uncontrolled active infection requiring intravenous antibiotics at the time of registration
- Transmural myocardial infarction ≤ 6 months prior to registration
- Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration
- Life-threatening uncontrolled clinically significant cardiac arrhythmias
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Uncontrolled psychiatric disorder
- Will receive any other investigational agent or chemotherapy and/or target therapies during treatment
- Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stereotactic ablative radiotherapy
Image-guided stereotactic ablative radiotherapy
|
SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local control (Response Evaluation Criteria In Solid Tumors version 1.1)
Time Frame: 12 months
|
Number of participant with local progression of index metastatic lymph receiving stereotactic ablative radiotherapy, assessed on CT scan according to Response Evaluation Criteria In Solid Tumors version 1.1
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Number of participant alive
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Acute toxicity (Common Toxicity Criteria for Adverse Events version 4)
Time Frame: From date of radiotherapy until 90 days after radiotherapy starts
|
Common Toxicity Criteria for Adverse Events version 4
|
From date of radiotherapy until 90 days after radiotherapy starts
|
Late toxicity (Common Toxicity Criteria for Adverse Events version 4)
Time Frame: From 90 days after radiotherapy starts until the date of death from any cause, up to 60 months
|
Common Toxicity Criteria for Adverse Events version 4
|
From 90 days after radiotherapy starts until the date of death from any cause, up to 60 months
|
Patient reported outcome (Quality of Life questionnaire)
Time Frame: at 1, 3 months after radiotherapy, and every 3 month thereafter until unequivocal progression, hospice care, or death, assessed up to 12 months
|
EORTC Quality of Life-Core 30 questionnaire module
|
at 1, 3 months after radiotherapy, and every 3 month thereafter until unequivocal progression, hospice care, or death, assessed up to 12 months
|
Metastatic nodal progression
Time Frame: From date of enrolment until the date of first documented metastatic nodal progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Number of participant with nodal progression on CT scan
|
From date of enrolment until the date of first documented metastatic nodal progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of peripheral blood lymphocyte subpopulations
Time Frame: at baseline, 2 weeks, 1, 2, 3, 6, and 12 months after radiotherapy
|
T-cell subpopulation (CD3/4/8/19/16+56)
|
at baseline, 2 weeks, 1, 2, 3, 6, and 12 months after radiotherapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201601023RINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastasis of Malignant Neoplasm to Lymph Node
-
Haukeland University HospitalUniversity of BergenCompletedSecondary Malignant Neoplasm of Lymph Node | Disorder of Upper Gastrointestinal Tract | Pancreatic Nodule | Secondary and Unspecified Malignant Neoplasm of Retroperitoneal Lymph NodesNorway
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversitySun Yat-sen UniversityUnknownDetection Rate of SLN ; Accuracy Rate of Lymph Node MetastasisChina
-
South Eastern Health and Social Care TrustUnknownNeoplasm Metastasis | Skin Neoplasms | Secondary Malignant Neoplasm of Lymph Node | Non-healing Surgical Wound (Disorder)United Kingdom
-
Universitätsklinikum Hamburg-EppendorfRecruitingColon Carcinoma | Lymph Node MetastasesGermany
-
Javeriana UniversityHospital Universitario San Ignacio; Fundación Santa Fe de Bogota; Fundación Cardioinfantil...CompletedProstatic Neoplasms | Secondary Malignant Neoplasm of Lymph NodeColombia
-
Luzerner KantonsspitalRecruitingLung Cancer | Lymph Node MetastasisSwitzerland
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Chonnam... and other collaboratorsCompletedStomach Neoplasms | Cancer of Lymph Node
-
Istituto Oncologico Veneto IRCCSCompletedMelanoma | Secondary Malignant Neoplasm of Lymph Node
-
Peking University People's HospitalUnknownLymph Node Metastases | Immune Microenvironment | Luminal AChina
Clinical Trials on Stereotactic ablative radiotherapy
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchActive, not recruiting
-
Barts & The London NHS TrustRecruitingHeart Failure | Ventricular Tachycardia | Radiotherapy; Complications | Structural Heart AbnormalityUnited Kingdom
-
University Health Network, TorontoRecruiting
-
Second Xiangya Hospital of Central South UniversityCompletedSterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy (SELECT)Hypertrophic Obstructive CardiomyopathyChina
-
Lawson Health Research InstituteUniversity of British Columbia; Western University, Canada; London Health Sciences...Active, not recruitingNon Small Cell Lung Cancer | Interstitial Lung DiseaseCanada, United Kingdom
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRecruiting
-
Stanford UniversityVarian, a Siemens Healthineers CompanyActive, not recruitingEmphysemaUnited States
-
European Organisation for Research and Treatment...UnknownNon-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIGermany, Belgium, United Kingdom, Switzerland
-
University of Texas Southwestern Medical CenterWithdrawnTachycardia, VentricularUnited States